Physiological predictors of peak inspiRatory flow using Observed lung function results (POROS) : evaluation at discharge among patients hospitalized for a COPD exacerbation by Price, David B. et al.
© 2018 Price et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2018:13 3937–3946
International Journal of COPD
This article was published in the following Dove Press journal: 
International Journal of COPD
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3937
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S174371
Physiological predictors Of peak inspiratory 
flow using Observed lung function resultS 
(POrOs): evaluation at discharge among patients 
hospitalized for a COPD exacerbation
David B Price,1,2 sen Yang,1 
simon Wan Yau Ming,1 
antony hardjojo,1 
Claudia Cabrera,3,4 
andriana I Papaioannou,5 
stelios loukides,5 
Vicky Kritikos,6 sinthia 
Z Bosnic-anticevich,6 
Victoria Carter,7 
Paul M Dorinsky8
1Observational and Pragmatic research 
Institute Pte ltd, singapore, singapore; 
2Centre of academic Primary Care, 
Division of applied health sciences, 
University of aberdeen, aberdeen, UK; 
3global Medical affairs, astraZeneca r 
and D, Mölndal, sweden; 4Department 
of Medical epidemiology and 
Biostatistics, Karolinska Institute, 
stockholm, sweden; 52nd respiratory 
Medicine Department, Medical school, 
national and Kapodistrian University 
of athens, attikon general hospital, 
athens, greece; 6Woolcock Institute 
of Medical research, Quality Use of 
respiratory Medicines group, school 
of Medical sciences, University of 
sydney, glebe, australia; 7Optimum 
Patient Care, Cambridge, UK; 8Pearl – 
a member of the astraZeneca group, 
Durham, nC, Usa
Background: Peak inspiratory flow (PIF) as generated through the resistance of a dry powder 
inhaler (DPI) device is a critical patient-dependent maneuver impacting the success of DPI 
medication delivery. Despite its importance, it is not routinely measured in clinical practice. 
Little is currently known about the relationship, if any, between PIF through DPI devices, routine 
spirometry and disease outcomes.
Aim: The aim of this study was to identify potential predictors of PIF for different DPIs from 
spirometric parameters and patient characteristics and explore the association between PIF and 
follow-up events.
Patients and methods: A retrospective observational study at discharge among patients 
hospitalized for a COPD exacerbation at Attikon hospital, Athens, Greece. Spirometry was 
performed using an Easy on-PC™ spirometer. PIF was measured through four DPI resistances 
using the In-Check™ DIAL. Regression analyses were used to investigate the association 
between PIF through resistances and spirometric parameters obtained at discharge, comorbidities 
and demographic parameters.
Results: Forty-seven COPD patients (mean [±SD], age 71 [±9] years, 72% males, 51% cur-
rent smokers) were included in this study. Overall, 85% and 15% were classified as GOLD 
(2017) groups D and C, respectively. Most prevalent comorbidities were hypertension (70%) 
and cardiovascular disease (53%). In the final regression model, higher PIF was significantly 
associated with the following: higher FEV
1
 and % predicted peak expiratory flow (PEF) for 
Turbohaler® (R-squared value 0.374); higher FEV
1
 and diagnosis of gastroesophageal reflux 
disease (GERD) for Aerolizer® (R-squared value 0.209) and higher FEV
1
, younger age and 
diagnosis of ischemic heart disease (IHD) for Diskus® (R-squared value 0.350). However, 
R-squared values for all three devices were weak (,0.4).
Conclusion: The study did not provide evidence to support the use of surrogate measurements 
for PIF through device resistance, which could assist in determining the appropriateness of inhaler 
device type. Although PIF measurement is feasible in patients at discharge and could be a valu-
able addition to the standard of care in COPD management, it needs to be measured directly.
Keywords: hospital admission, COPD, dry powder inhaler devices, inhaler technique, 
resistance, spirometry
Introduction
COPD is a progressive, multicomponent and complex disease. Its association with 
multiple comorbidities increases the overall disease burden and health care costs.1–3 
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Advanced stages of COPD are accompanied by an increasing 
frequency and severity of exacerbations, which accelerate the 
decline in lung function, decrease health status and quality of 
life and are a leading cause of hospitalization and mortality.4,5 
Management is aimed at both improving symptom control 
and preventing or reducing exacerbations.1
Inhaled medications are the mainstay of pharmacological 
treatment of COPD, allowing for the rapid delivery of small 
doses of medication directly to the airways and reducing the 
risk of adverse effects due to lower systemic exposure vs 
oral administration.6,7 Effective inhaled treatments for COPD 
include bronchodilators and corticosteroids, most commonly 
delivered using pressurized metered dose inhalers (pMDIs) 
and dry powder inhalers (DPIs), each of which have different 
degrees of airflow resistance.8 These device types require 
different inhalation techniques to ensure optimal medica-
tion delivery. With pMDIs, coordination of actuation with 
slow and steady inspiration is required for adequate lung 
deposition.9 In contrast, successful drug delivery from a DPI 
requires an initial fast inhalation to generate sufficient peak 
inspiratory flow (PIF) through the device to overcome the 
resistance within the device and is dependent on the patient’s 
level of effort and respiratory muscle strength.10,11 An optimal 
PIF which can be sustained for 2–3 seconds is needed to 
deaggregate drug particles and disperse the powder into 
finer particles suitable for lung deposition.10,12 Furthermore, 
the inspiratory effort required for successful drug delivery 
varies depending on the resistance within the DPI device.13 
PIF as generated through the mouthpiece of a DPI device is 
a critical patient-dependent maneuver impacting the success 
of DPI medication delivery.14
Poor inhaler technique is common among COPD 
patients,15,16 with up to 68% using their inhalers incorrectly16 
and nearly 30% failing to achieve a forceful inspiratory flow 
depending on the DPI device.17 In the CRITIKAL study, 
inhaler technique errors related to inspiratory effort were 
found to be common, and actuation before inhalation in 
pMDI users and insufficient inspiratory effort in DPI users 
were shown to be frequent critical errors associated with poor 
asthma outcomes.18 Inhaler misuse can also lead to reduced 
effectiveness of treatment, influence patient adherence to 
therapy and has been associated with increased health care 
utilization and poor COPD outcomes.17,19–25 Thus, when 
initiating and monitoring therapy through a DPI device, it is 
important to check whether a patient has the ability to inhale 
with sufficient inspiratory effort to use a specific DPI device 
so that they receive the optimal dose of medication. Despite 
the important role of PIF in the context of DPI technique, 
it is not routinely measured in clinical practice. Part of this 
may be due to the fact that PIF from spirometry has been 
used as a surrogate measure of PIF through a device, but 
spirometric PIF is at zero resistance and thus may be mis-
leading. Little is currently known about the relationship, if 
any, between PIF through DPI devices, routine spirometry 
and disease outcomes.
Evidence is needed to better understand the relationship 
between PIF, proper device use and clinical outcomes among 
COPD patients. Recently, a retrospective study found that 
COPD patients with suboptimal PIFs that were obtained at zero 
resistance had fewer days to readmission after discharge for a 
severe exacerbation.26 In addition, while a limited number of 
studies have measured PIFs against different imposed resis-
tance levels in stable COPD outpatients,27–32 and in patients at 
discharge following a COPD exacerbation,24,26,32 results from 
these studies indicate that suboptimal PIFs were prevalent in 
these two subgroups. Since PIF through a DPI device is not 
routinely measured in clinical practice, it is important to deter-
mine whether or not routine lung function tests coupled with 
routine demographic and clinical parameters such as severity 
of breathlessness and comorbidities can contribute to the pre-
diction of PIF through a DPI or whether PIF needs to be mea-
sured directly. Finding a proxy for PIF through a DPI would be 
valuable in determining the appropriateness of inhaler device 
type and improving COPD treatment strategies.
Therefore, the present study was designed to identify 
whether predictors of PIF for different DPIs among inpa-
tients at the time of discharge could be determined based 
on spirometric parameters and patient characteristics and to 
explore the association between PIF and follow-up events, 
including time to an exacerbation following discharge with 
or without hospitalization.
Materials and methods
study design
This retrospective observational study used data from patients 
with COPD admitted to a single hospital in Greece for a 
COPD exacerbation between January 2016 and September 
2016. Baseline data were collected over a 1-year period 
prior to discharge (index date), and patients were followed 
until death or until April 2017 after discharge (outcome 
period) using primary and secondary care data. Ethical 
approval was obtained from the Attikon University Hospital, 
Chaidari, Athens, Greece (approval number 575/7-1-15). 
All participants gave written informed consent.
study population
Patients were included in the study if all the following 
inclusion criteria were met: they had a diagnosis of COPD on 
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admission to the Attikon hospital respiratory unit in Athens 
(Greece) based on the GOLD (2017) strategy;33 they were 
discharged from hospital (index date) to the community 
following the hospital admission for a COPD exacerbation, 
and they had spirometry during admission and PIFs obtained 
through an In-Check™ DIAL on the same day of discharge. 
Patients were excluded from the study if they had a diagnosis 
of asthma or any chronic respiratory disease other than 
COPD, or their PIF measurements were not obtained on the 
same day of discharge.
Data sources
The study used anonymized patient data from Attikon 
hospital, Athens, Greece. The database is a combination of 
electronic health records of patients admitted to hospital with 
a COPD-related exacerbation and prescription data obtained 
from a database that includes primary care prescriptions. 
The database includes information on diagnosis of comor-
bidities, lung function tests, previous medications (gathered 
via the national electronic prescription system), inpatient 
prescriptions, discharge medications, non-invasive ventila-
tion and length of hospital stay. Post bronchodilator (PB) lung 
function tests were recorded in this database using a portable 
PC-based spirometer, the Easy on-PC™ Spirometer (ndd 
Medizintechnik, Zurich, Switzerland), which meets all the 
American Thoracic Society/European Respiratory Society 
(ATS/ERS) recommendations for diagnostic spirometers.34 
Lung function tests were performed according to the ATS/
ERS 2005 guidelines.34 The data set also includes PB PIF 
measurements through the In-Check DIAL (Clement Clarke 
International Ltd., Harlow, UK), which is a portable inspira-
tory flow meter with an adjustable dial that can be set at zero 
resistance or set to simulate the resistance characteristics of 
common DPIs.35 It was set to simulate the following four 
DPI devices with varying resistance levels: low – Aerolizer® 
(Merck & Co., Inc., Whitehouse Station, NJ, USA); medium/
low – Diskus® (GlaxoSmithKline plc, London, UK); medium/
high – Turbohaler® (AstraZeneca plc, London, UK or 
Södertälje, Sweden) and high – Handihaler® (Boehringer 
Ingelheim, Ingelheim, Germany). The In-Check DIAL is 
capable of measuring inspiratory flow rates between 0 and 
120 L/min and is calibrated with an ATS waveform generator, 
with a reported accuracy rate of 10% or 10 L/min.35
study variables
Demographic data were collected including age (closest to 
the index date), gender, body mass index (BMI) (closest 
to the index date) and smoking status (closest to the index 
date) (further details and variable definitions are provided 
in Supplementary material S1 and Table 1). Comorbidities 
were recorded any time prior to the index date – as a yes/no 
response in the study-specific data collection form based on 
Table 1 Unadjusted associations between spirometric parameters and PIF through each In-Check™ DIal resistance setting
In-Check DIAL  
resistance setting
Covariates Simple linear regression
Unstandardized coefficient B (95% CI) R-squared statistic
aerolizer® FeV1 18.4 (2.6, 34.3) 0.109
 FeV1/FVC 20.6 (-31.2, 72.5) 0.014
 % predicted FVC 0.40 (-0.09, 0.89) 0.056
 % predicted FeV1 0.29 (-0.11, 0.69) 0.045
 log(FeF25–75) 8.4 (-3.5, 20.3) 0.046
 % predicted PeF 0.47 (0.10, 0.84) 0.133
Diskus® FeV1 19.9 (6.8, 33.0) 0.172
 FeV1/FVC 23.7 (-20.5, 67.9) 0.025
 % predicted FVC 0.39 (-0.03, 0.81) 0.071
 % predicted FeV1 0.29 (-0.05, 0.63) 0.061
 log(FeF25–75) 7.4 (-2.6, 17.4) 0.050
 % predicted PeF 0.41 (0.09, 0.74) 0.134
Turbohaler® FeV1 16.1 (7.2, 24.9) 0.230
 FeV1/FVC 28.7 (-1.4, 58.8) 0.076
 % predicted FVC 0.39 (0.11, 0.67) 0.151
 % predicted FeV1 0.35 (0.13, 0.58) 0.180
 log(FeF25–75) 9.0 (2.4, 15.5) 0.152
 % predicted PeF 0.43 (0.22, 0.63) 0.294
Note: Bold values represent significant univariate associations between spirometric parameters and PIF through each imposed resistance setting.
Abbreviations: FeF25–75, forced expiratory flow 25–75; FVC, forced vital capacity; PEF, peak expiratory flow; PIF, peak inspiratory flow.
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information from the database or patient-reported outcomes. 
Lung function tests were recorded every day during hospital-
ization (measurement closest to the day of PIF measurement 
was used as baseline) and included the following: FEV
1
; 
FVC; FEV
1
/FVC; percent predicted FEV
1
; forced expira-
tory flow 25–75 (FEF
25–75
) and peak expiratory flow (PEF). 
PIF measurements through In-Check DIAL set at different 
resistances were obtained by resident doctors on the day of 
discharge. Patients were instructed to breathe in “fast and 
hard” through the device following exhalation to residual 
volume (RV), and the best PIF out of three consecutive 
measurements was recorded.
The following variables were recorded 1 year prior to the 
index date (ie, during the baseline year): GOLD 2017 group 
classification;33 Modified British Medical Research Council 
(mMRC) score;33 Modified BORG dyspnea scale;36 and type 
of COPD exacerbation according to Anthonisen criteria37 
and exacerbation severity (variable definitions are provided 
in Supplementary material S1; Table 1). The following pre-
scriptions were recorded during the baseline year from the 
prescription database: short-acting β
2
 agonist (SABA) and/or 
short-acting muscarinic antagonist (SAMA); long-acting mus-
carinic antagonist (LAMA); long-acting β
2
 agonist (LABA); 
inhaled corticosteroids (ICSs) and fixed dose combinations 
of ICS/LABA, LABA/LAMA and SABA/SAMA.
Data analyses
Summary statistics were calculated for baseline variables 
including mean, SD, median, IQR, minimum and maximum 
for continuous variables and counts and percentages for 
categorical variables. Doses of ICS containing medication 
were categorized into low, medium and high (Supplementary 
material S1; Table 2). The last recorded measurement before 
discharge was summarized for all lung function tests and 
PIFs through In-Check DIAL. Box plots were used to depict 
the distributions of PIF by categorical baseline variables 
(eg, gender, smoking status and comorbidities). Correlation 
matrices were used to examine the relationship between PIF 
through In-Check DIAL and continuous baseline variables 
(eg, age and spirometric parameters). This procedure was 
performed separately for PIF recorded through the In-Check 
DIAL for each resistance setting. Simple and multivariable 
linear regressions were used to investigate the association 
between PIF and spirometric parameters (individually and 
in combination). Multivariable linear regression was used 
to investigate the association between PIF and spirometric 
parameters and additional baseline covariates. Potential 
covariates were chosen based on the examination of the box 
plots and correlation matrices.
An exploratory analysis of the association between PIF 
and exacerbations following discharge was performed, and 
scatter plots of time to event against PIF were examined for 
each resistance setting. Outcomes included the following: 
acute exacerbation following discharge with hospitalization; 
acute exacerbation following discharge without hospitaliza-
tion and no acute exacerbations from the time of discharge 
to data collection. Kaplan–Meier plots of the probability of 
remaining hospitalization-free following discharge for each 
resistance setting and by PIF categories (,30 and $30 L/min 
for Handihaler; ,60 and $60 L/min for Aerolizer, Diskus 
and Turbohaler) were also examined. An exploratory analysis 
of time to acute exacerbation with hospitalization by baseline 
COPD medication (categorized by medication class) groups 
was also performed. The baseline medication groups were 
as follows: stable – patients who did not change medication; 
additional – those patients who received additional therapy 
and dropped – those patients who dropped therapy. All sta-
tistical analyses were performed using SAS version 9.4 and 
R version 3.4.0.4.
Results
Patient population
A flow diagram of the participant screening and selection 
process is summarized in Figure 1. The final study sample 
included 47 COPD patients over the study time period. 
The mean (±SD) age of patients was 71 (±9) years with 
35 (75%) patients aged $65 years, 34 (72%) were male, 
17 (36%) had a BMI of $30 and over half were current 
Table 2 Multivariable association of spirometric parameters with PIF through each In-Check™ DIal resistance setting
In-Check DIAL 
resistance setting
Covariates Multivariable linear regression
Standardized coefficient beta (95% CI) R-squared statistic AIC
aerolizer® FeV1 18.0 (2.6, 34.3) 0.109 289.2
Diskus® FeV1 19.9 (6.8, 33.0) 0.172 271.3
Turbohaler® FeV1 11.8 (1.5, 22.0) 0.374 216.3
 % predicted PeF 0.26 (0.01, 0.50)   
Abbreviations: AIC, area inside the curve; PEF, peak expiratory flow; PIF, peak inspiratory flow.
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Figure 1 Participants’ flow diagram.
smokers. The most prevalent comorbidity was hyperten-
sion (70%), followed by cardiovascular disease (ie, heart 
failure, arrhythmias, stroke and pulmonary or vascular 
disorders) (53%) and ischemic heart disease (IHD) (38%) 
(Supplementary material S2; Table 1). The mean (±SD) 
length of stay of index hospitalization was 8 (±2) days.
On admission to hospital, 24 (51%) patients were cat-
egorized as being on a high dose of ICS, and on discharge, 
this proportion reduced to 30%. The most prevalent COPD 
treatment combination was ICS plus a fixed dose of SABA/
SAMA (30%), followed by a fixed dose of ICS/LABA plus 
LAMA (23%) (Supplementary material S2; Table 1). Of the 
47 patients, 25 (53%) patients had stable COPD medication 
during the baseline year; 12 (26%) patients were prescribed 
additional medications (mainly ICS) during that time; five 
(11%) patients had at least one of their therapies dropped; 
three (6%) patients were not receiving any treatment and two 
(4%) patients had insufficient data to be categorized.
The majority of patients (89%) were admitted to the 
hospital for a Type 1 exacerbation, with 40 (85%) patients 
classified as GOLD (2017) group D and seven (15%) as 
group C. Overall, 31 (70%) patients had at least one moderate 
exacerbation during the baseline year. All patients had a hos-
pitalization for a severe exacerbation during the baseline year, 
with 13 (30%) having two or more severe exacerbations dur-
ing the baseline year (Supplementary material S2; Table 2). 
The mean FEV
1
 was 39% predicted: only one (2%) patient 
was classified as “mild” with an FEV
1
 $80% predicted, 
whereas 21 (45%) and 17 (36%) patients had “severe” and 
“very severe” airflow limitation, respectively (Supplementary 
material S2; Table 3).
associations between spirometric 
parameters and PIF
For Aerolizer, Diskus and Turbohaler, significant univariate 
associations were noted between FEV
1
 (R-squared values 
0.109, 0.172 and 0.230, respectively), % predicted PEF 
(R-squared values 0.133, 0.134 and 0.294, respectively) 
and PIF (Table 1). Additionally, for Turbohaler, significant 
associations were also noted between % predicted FVC 
(R-squared value 0.151), % predicted FEV
1
 (R-squared 
value 0.180) and log (FEF
25–75
) (R-squared value 0.152) and 
PIF. Despite statistical significance, the R-squared statistics 
indicate that only a small proportion of variance could be 
explained by the covariates (Table 1). Regression results for 
Handihaler are not presented as data did not allow for ade-
quate model fit, and changing to a binary logistic regression 
was not possible due to small numbers in the categories.
In multivariable analysis, FEV
1
 was the only vari-
able retained for Aerolizer and Diskus (R-squared values 
0.109 and 0.172, respectively), whereas for Turbohaler, 
the best model for prediction of PIF included both FEV
1
 
and % predicted PEF, although the R-squared value (0.374) 
Table 3 Multivariable association of spirometric parameters and other variables with PIF through each In-Check™ DIal resistance 
setting
In-Check DIAL  
resistance setting
Covariates Multivariable linear regression
Standardized coefficient beta (95% CI) R-squared statistic AIC
aerolizer® FeV1 17.0 (1.8, 32.2) 0.209 285.6
 gerD 15.6 (2.3, 29.0)   
Diskus® FeV1 16.0 (3.8, 28.2) 0.350 263.9
 age -0.91 (-1.5, -0.35)   
 IhD 10.5 (0.14, 20.9)   
Turbohaler® FeV1 11.8 (1.5, 22.0) 0.374 216.3
 % predicted PeF 0.26 (0.01, 0.50)   
Abbreviations: AIC, area inside the curve; GERD, gastroesophageal reflux disease; IHD, ischemic heart disease; PEF, peak expiratory flow; PIF, peak inspiratory flow.
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was not strong (Table 2). Thus, associations between PIF and 
spirometric parameters were either absent or, when present, 
weak, indicating that routine spirometry is not adequately 
able to serve as a surrogate for PIF against resistance.
Distributions of PIF by categorical 
baseline variables
PIF distributions by categorical baseline variables showed 
that higher median PIFs through at least one device appeared 
to be associated with male gender, current smokers and 
a diagnosis of gastroesophageal reflux disease (GERD), 
osteoporosis, IHD, diabetes or GOLD group (Supplementary 
material S2; Figures S1–S6 and S8). In contrast, patients 
in the highest mMRC category appeared to have lower 
median PIF through Aerolizer and Diskus than those in 
the lower mMRC categories (Supplementary material S2; 
Figure S7).
Correlations between PIF and continuous 
baseline variables
For all resistance settings, while there was a small positive 
correlation between PIF and % predicted PEF and FEV
1
, 
there was a negative correlation between PIF and age 
(Supplementary material S2; Figure S9A–D). Moreover, for 
Turbohaler only, PIF appeared to positively correlate with 
FEF
25–75
, % predicted FEV
1
, % predicted FVC and FEV
1
/
FVC (Supplementary material S2; Figure S9D).
associations between spirometric 
parameters, demographic and clinical 
characteristics and PIF
For Turbohaler, the final regression model was not improved 
by other covariates and so included only FEV
1
 and % 
predicted PEF (R-squared value 0.374). For Aerolizer, in 
addition to FEV
1
 as a covariate, diagnosis of GERD was sig-
nificantly associated with higher PIF (R-squared value 0.209). 
For Diskus, the final multivariable model included FEV
1
, age 
and diagnosis of IHD (R-squared value 0.350). Older age 
was associated with lower PIF, whereas diagnosis of IHD 
was associated with higher PIF. However, R-squared values 
of the regression models for all three devices were weak 
(,0.4) (Table 3). Regression for Handihaler did not allow 
for adequate model fit and thus was not further analyzed.
associations between PIF and follow-up 
events
There were no clear associations between PIF at discharge 
and time to acute exacerbation with hospitalization, time to 
acute exacerbation without a hospitalization or time free of 
exacerbations (Supplementary material S3; Figures S1–S3). 
PIFs ,60 L/min were observed in 10 patients (21%) for 
Aerolizer, 17 patients (36%) for Diskus, 32 patients (68%) 
for Turbohaler and with PIFs ,30 L/min in six patients 
(13%) for Handihaler (Supplementary material S3; Table 1). 
The number of patients readmitted to the hospital for acute 
exacerbations with PIF ,60 and $60 L/min were as fol-
lows: for Aerolizer, 6 (13%) and 15 (32%), respectively; for 
Diskus, 9 (19%) and 12 (26%), respectively; for Turbohaler, 
15 (32%) and 6 (13%), respectively, and with PIF ,30 
and $30 L/min, for Handihaler, it was 4 (9%) and 17 (36%), 
respectively (Supplementary material S3; Table 2). For all 
devices except Diskus, mean time to readmission was shorter 
in the higher PIF category, with Turbohaler appearing to 
have the largest difference in mean days to readmission 
(Supplementary material S3; Figure S4). For Aerolizer 
and Handihaler, the probability of remaining hospital-free 
following discharge seemed to be lower for patients with 
PIF ,60 and ,30 L/min, respectively, although this was 
not statistically significant (Supplementary material S3; 
Figure S5). There was no difference in the probability of 
remaining hospital-free between ,60 and $60 L/min PIF 
groups for Turbohaler and Diskus. When the study sample 
was categorized by baseline COPD medication groups, 
median time to acute exacerbation with hospitalization 
seemed to be longest for patients who had a therapy added 
(n=12 [29%]) during the baseline year (123 days [IQR, 
45–183]) and shortest for patients who had a therapy 
dropped (14 days [IQR, 11–53]) (Supplementary material 
S3; Table 3).
Discussion
This study among hospitalized COPD patients, to our 
knowledge, is the first to explore the relationship between 
PIF against DPI device resistance at the time of discharge 
and patient characteristics and lung function parameters 
as well as follow-up events. Although our study showed 
the feasibility of measuring PIF against DPI resistance in 
patients with COPD at discharge, no variable individually 
or in combination was useful in predicting those with low 
PIF against imposed resistance, suggesting that PIF against 
resistance needs to be measured directly.
The strength of the study lies in the fact that it is the first 
retrospective observational study to explore associations 
between a combination of baseline patient characteristics 
and spirometric parameters and PIFs through four differ-
ent resistances corresponding to DPI devices at the time of 
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discharge. The study focused on a patient cohort at discharge 
following hospitalization for a severe COPD exacerbation, 
because DPIs are often prescribed without information on PIF 
for this population, an often elderly population with advanced 
stages of COPD, high symptom burden, multi-morbidity and 
at greatest risk of future exacerbations. Therefore, it was 
important to test the feasibility of measuring PIF through 
imposed resistance at the time of discharge in this vulner-
able population. Finally, PIF measurements were obtained at 
discharge against four different resistance settings from RV, 
which is easier and practical to perform in clinical practice 
than from functional residual capacity.
The study found a small positive correlation between PIF 
and FEV
1
 and % predicted PEF across all imposed resistance 
settings and, for three of the devices, also identified predic-
tors of PIF though none were strong: Aerolizer (FEV
1
 and 
diagnosis of GERD), Diskus (FEV
1
, younger age and diag-
nosis of IHD) and Turbohaler (FEV
1
 and % predicted PEF). 
Altogether, these findings strongly suggest that PIF against 
device resistance needs to be measured directly.
Previous studies have also found correlations between 
PIF and various spirometric parameters; however, correla-
tions between PIF through resistance and both FEV
1
 and 
% predicted FEV
1
 have been shown to be inconsistent,27,28,30,32 
and hence, decision on inhaler device selection should 
not be based on FEV
1
 alone. PIF and FEV
1
 also reflect 
extrapulmonary and pulmonary dynamics, respectively, 
and hence our findings are not surprising. PIF is a marker of 
inspiratory muscle strength, which can improve significantly 
with endurance training.38 Aging, arthritis and malnutrition 
can also contribute to reduced respiratory muscle strength, 
which reduces PIFs.39,40 Although no correlations were found 
between PIF and FVC in this study, reduced vital capacity 
has been shown to correlate with PIF in multiple studies, 
suggesting that other factors beyond airflow limitation, such 
as respiratory muscle insufficiency, hyperinflation or air 
trapping, may be good predictors of low PIF.27,28,32 Although 
increasing age24,26–31 and female gender24,28,30,32 have consis-
tently been shown to correlate with decreasing PIFs among 
COPD patients in general, no associations were found 
between gender and PIFs across resistances in this study. 
A possible explanation could be the predominance of males 
in our patient cohort, who have higher overall values for lung 
function including inspiratory mouth pressures than women,41 
and thus with fewer females in our cohort we detected no sig-
nificant correlations between female gender and decreasing 
PIF. In a recent study among COPD inpatients at discharge,24 
pneumonia and IHD were found to be associated with lower 
PIFs through Diskus, which are inconsistent with our study 
findings that suggested that GERD and IHD were associated 
with higher PIFs using Aerolizer and Diskus, respectively. 
The clinical reasons for these findings are unclear and could 
be a reflection of confounders due to low sample size and/or 
multiple analysis effects. Future research studies that are 
adequately powered are needed to confirm our findings.
In this study, a cutoff at a PIF less than 30 L/min for 
Handihaler and PIF less than 60 L/min for Aerolizer, Diskus 
and Turbohaler were made in order to distinguish optimal 
flows from suboptimal levels based on a review of the current 
literature.42,43 Previous studies have measured PIF through 
different resistances mainly in clinically stable COPD 
patients and few studies have used similar cutoffs to this 
study.27–32 In elderly, stable COPD patients, Janssens et al27 
found that among 26 patients, 12.5% had suboptimal PIF 
(defined as ,45 L/min) using Aerolizer, 20% using Diskus 
and 30% using Turbohaler, whereas Mahler et al28 found 
that among 213 patients, 19% had suboptimal PIF (defined 
as ,60 L/min) using Diskus. In our inpatient cohort, the 
prevalence of suboptimal PIF through Aerolizer, Diskus 
and Turbohaler at discharge was higher than that observed 
in a previous study of clinically stable patients with severe 
COPD.27 This reinforces the view that COPD exacerba-
tions can significantly reduce PIF during the acute phase as 
hyperinflation is prevalent and inspiratory muscle function 
is often compromised,44,45 and while a reduced PIF may not 
vary substantially during the acute exacerbation time frame,44 
this reduction may continue for a few months following 
discharge.32 Thus, PIF measurement at discharge plays a 
critical role in determining if an elderly patient can use or 
continue to use a particular DPI device, as their ability to 
generate sufficient inspiratory flow is often compromised 
following a COPD exacerbation.
This study found no strong associations between PIF 
through any of the resistance settings at the time of discharge 
and time to event outcomes. Furthermore, for all devices 
except for Diskus, the higher PIF group (while the lower PIF 
group for Diskus) appeared to have had fewer days to COPD 
readmission. These findings are inconsistent with those from 
a previous retrospective study, which found that the lower PIF 
group (defined as ,60 L/min against zero resistance) had sig-
nificantly fewer days to COPD readmission and that PIF was 
the only significant variable associated with readmission.26 
Additionally, our results seem to suggest that patients with 
Aerolizer PIF ,60 L/min and patients with Handihaler 
PIF ,30 L/min have a higher probability of being readmitted 
for an acute exacerbation. It is possible that our results could 
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be confounded by the very small sample size and that some 
patients were either not using ICS or using low-dose ICS on 
admission and a greater proportion were using moderate-to 
high-dose ICS at discharge, suggesting that the initial event 
may have been a consequence of undertreatment.
Limitations
There are some limitations to this study, which could affect 
the generalizability of the results. The retrospective design of 
the study, and the setting of a single hospital, meant that the 
final sample size was small, which could explain the weak 
association between PIF and follow-up events. Furthermore, 
as this observational study was conducted under conditions 
of real-life clinical practice, it meant that all lung function 
tests including PIFs among hospitalized COPD patients were 
performed post bronchodilation, which may have further 
weakened the association between PIF and follow-up events. 
Another limitation of the study is the multiple analysis effect, 
where up to 5% of the comparisons could yield positive 
results by chance alone, and therefore some unexplained 
results may have been only by chance. Finally, while our 
study was able to determine additional “class” of therapy 
taken during the baseline year, it was not possible to deter-
mine after discharge whether additional drug delivery devices 
(eg, nebulizers, spacers) were being used, and/or inhaler tech-
nique training, smoking cessation or pulmonary rehabilitation 
(endurance training) had been undertaken, as these factors 
could potentially affect follow-up events. Nevertheless, this 
research could not identify any strong predictors of PIF for 
different DPIs among inpatients at the time of discharge, 
suggesting that PIF against resistance needs to be measured 
directly. PIF measured against resistance in the clinical 
setting can be a useful tool to guide treatment options for a 
COPD population at greatest risk of future adverse outcomes. 
Measurement of PIF against resistance may not only help to 
personalize device selection (pMDI vs DPI) and even DPI 
selection but may also help to identify patients with reduced 
PIFs who could benefit from either pulmonary rehabilitation 
programs that focus on improving inspiratory muscle strength 
leading to increased PIF and thus better drug delivery or from 
dual bronchodilation in addition to ICS, which may help to 
improve inspiratory capacity and thus PIF.
Conclusion
The results of this study have important clinical implications. 
First, this study did not provide strong evidence to support 
the use of surrogate measurements for PIF through device 
resistance, which could assist in selecting appropriate inhaler 
devices in patients with COPD. Although PIF measurement 
against resistance would be a valuable addition to the 
standard of care in the management of COPD, it needs to be 
measured directly. Second, this study showed the feasibility 
of measuring PIF against resistance in patients with COPD at 
discharge. Further studies are needed to define the impact of 
PIF, device selection and outcomes after discharge following 
a COPD exacerbation.
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